Skip Navigation
Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
AHRQ Home | Questions? | Contact Us | Site Map | What's New | Browse | Información en español | E-mail UpdatesE-mail Updates
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Search Results to Slide Tray Search:

"adverse outcomes"

Slides: 1–9 of 9
Add to tray Remove from tray

Background: The “No-Reflow Phenomenon” After PCI

Presentation: Adjunctive Devices for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Keywords: background | no reflow | percutaneous coronary intervention | atherothrombotic material | adverse outcomes
Add to tray Remove from tray

Adjunctive Catheter Aspiration Thrombectomy Versus PCI Alone in Patients With STEMI: Adverse Events

Presentation: Adjunctive Devices for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Keywords: adjunctive device | catheter aspiration | percutaneous coronary intervention | PCI | ST-segment elevation myocardial infarction | STEMI | coronary dissection | procedure time
Off-Label Uses of rFVIIa The use of rFVIIa for off-label clinical indications originates in the ability of rFVIIa to “bypass” multiple defects in the coagulation pathway. These uses are listed by their relative proximity to the FDA approved uses. The following categories suggest increasing extension of rFVIIa use into clinical areas with diminishing similarity to the FDA approved uses. Chronic prophylactic use in hemophilia A and B in the absence of bleeding episodes or procedures. While not approved by the FDA, this form of use has been approved in Australia. Episodic use in other congenital and acquired clotting factor defects, including hemophilia C, von Willebrand’s disease, and factor VII deficiency, as well as in other rare coagulopathies. Episodic use for isolated congenital or acquired clotting defects that arise from deficiency or dysfunction of other components of the coagulation process. This includes platelet dysfunction, such as Glanzmann’s thrombasthenia, which has been approved by the EMEA but not the FDA. Episodic use in disease states where impaired coagulation is but one manifestation. Liver disease is a prominent example, but other conditions include leukemia, lymphoma, and other cancers. Episodic use where anticoagulant therapy contributes to bleeding problems beyond what would exist otherwise. This includes patients on warfarin and those undergoing cardiac surgery with cardiopulmonary bypass that requires heparin anticoagulation. Clinical circumstances where a consumptive coagulopathy has developed as the result of substantial and rapid blood loss. In practice, this often includes trauma patients and those with massive gastrointestinal bleeding. Situations where significant blood loss is anticipated in the absence of pre-existing coagulopathy, as with prophylactic use of rFVIIa in prostatectomy or vascular surgery. Clinical situations requiring prompt cessation of traumatic, surgical, or spontaneous bleeding in non-coagulopathic patients where hemorrhage extension is associated with significant adverse outcomes, as occurs with intracranial hemorrhage, brain surgery, and pulmonary hemorrhage.
Add to tray Remove from tray

Off-Label Uses of rFVIIa

Presentation: Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care
Keywords: bleeding | clotting factor defects | consumptive coagulopathy | hemophilia | off-label uses | recombinant factor VIIa | comparative effectiveness
Add to tray Remove from tray

Background: Treatment of GERD (2 of 2)

Presentation: Comparative Effectiveness of Management Strategies for Adults With Gastroesophageal Reflux Disease: An Update
Keywords: endoscopic | H2RA | histamine type 2 receptor antagonist | lifestyle modification | PPI | proton pump inhibitor | surgery | treatment
Add to tray Remove from tray

Background: Diagnosis of Obstructive Sleep Apnea (3 of 3)

Presentation: Diagnosis and Treatment of Obstructive Sleep Apnea in Adults
Keywords: AHI | apnea-hypopnea Index | background | diagnosis | measurement of severity | clinical features
Add to tray Remove from tray

Background: Associated Adverse Outcomes

Presentation: Management of Chronic Kidney Disease Stages 1–3
Keywords: adverse outcomes | chronic kidney disease
Add to tray Remove from tray

Comparative Effectiveness of Pharmacological or Mechanical Thromboprophylaxis Versus No Thromboprophylaxis

Presentation: Venous Thromboembolism Prophylaxis in Orthopedic Surgery
Keywords: hip fracture surgery | mechanical thromboprophylaxis | orthopedic surgery | pharmacological thromboprophylaxis | total hip replacement | total knee replacement | comparative effectiveness
Add to tray Remove from tray

Comparative Effectiveness of Pharmacological and Mechanical Prophylaxis Agents

Presentation: Venous Thromboembolism Prophylaxis in Orthopedic Surgery
Keywords: comparative effectiveness | mechanical prophylaxis | pharmacological prophylaxis | thromboprophylaxis | venous thromboembolism | orthopedic surgery
Add to tray Remove from tray

Comparative Effectiveness of Prolonged (=28 Days) Versus Standard (7–10 Days) Pharmacological Prophylaxis

Presentation: Venous Thromboembolism Prophylaxis in Orthopedic Surgery
Keywords: compression stockings | dalteparin | dextran | enoxaparin | hip fracture surgery | low-molecular-weight heparin | pharmacological prophylaxis | prolonged prophylaxis | standard-duration prophylaxis | total hip replacement | total knee replacement | vitamin K antagonist | warfarin | orthopedic surgery
 
 
 
 
www.ahrq.gov AHRQ Home | Questions? | Contact AHRQ | Site Map | Accessibility | Privacy Policy | Freedom of Information Act | Disclaimers
U.S. Department of Health & Human Services | The White House | USA.gov: The U.S. Government's Official Web Portal

Agency for Healthcare Research and Quality • 540 Gaither Road Rockville, MD 20850 • Telephone: (301) 427-1364